

APRIL 2024 - ISSUE 29

# WAMJ

World Asian Medical Journal

Inspirational Asian  
Healthcare Leader

## KYOUNG RYUL LEE

CEO of the SCL Group, a Specialist in Laboratory Medicine

### SPECIAL REPORT I


Innovation and Equity  
discussed at 24th New York  
Health Forum

### SPECIAL REPORT II

Prestigious Health Equity  
Award presented by New  
York Health Forum

### HEALTHCARE INDUSTRY REPORT

FemTech Supports Women in  
the Workforce



**KHIDI USA**  
Promoting Healthcare Industry

KHIDI USA helps acquire overseas authorization and to facilitate the US expansion of Korean Companies and institutions in the healthcare industry by serving as a bridge between Korea and the US.

**US MARKET  
ENTRY SUPPORT**

KHIDI USA helps Healthcare companies overcome the challenges they could face in a new market which often include language/cultural barrier, lack of market knowledge, and regulatory challenges.

**INVESTMENT  
SUPPORT**

With US market insights and a vast network of healthcare companies and service providers in both Korea and the US, KHIDI USA can support and connect those seeking investment opportunities in Korea or the US.

**INDUSTRY  
RESOURCES**

KHIDI USA constantly works to establish industry resources to acquire market intelligence and expand its US healthcare network through various networking and analysis efforts.

[www.khidiusa.org](http://www.khidiusa.org)  
[contact@khidiusa.org](mailto:contact@khidiusa.org)

Better Together  
Better Tomorrow

SCL Healthcare



**Research for a  
Healthier Future**

With world-class research and technology we are opening a new future in medicine



# The University of Chicago Medicine Welcomes You to the Forefront

## Where some of the greatest advances in medicine are hard at work for you.

The University of Chicago Medicine pioneers the kind of research that's changing lives. It is home to the most advanced medical technology, and physicians who work at the forefront of their fields.

It is our mission to bring the forefront of medicine to the world through personalized international patient services and tailored global advisory and education programs.

## Clinical Centers of Excellence

- » Comprehensive Cancer Center
- » Transplant Institute
- » Heart & Vascular Center
- » Neuroscience Center
- » Digestive Diseases Center
- » Orthopaedic Surgery
- » Obstetrics & Gynecology
- » Pediatrics

For more information, visit  
[UChicagoMedicine.org/global](http://UChicagoMedicine.org/global)



**100 Nobel Laureates,** including **12** in Physiology or Medicine



**Magnet Recognition** for Excellence in Nursing & Patient Care



One of only **22** acute-care facilities nationwide to receive "A" grade in patient safety from Leapfrog Group for **21 consecutive periods** as of May 2022



**Ranked nationally** in multiple adult and children's specialties by *U.S. News & World Report*



## Our Editorial Boards

|                        |  |   |
|------------------------|--|---|
| <b>PUBLISHER</b>       | Chul S. Hyun, MD, PhD, MPH   | Stomach Cancer Task Force   |
| <b>EDITOR IN CHIEF</b> | Joseph P. McMenamin, MD, JD, FCLM  | Christian & Barton, LLP   |
| <b>MANAGING EDITOR</b> | DoHyun Cho, PhD  | W Medical Strategy Group  |
| <b>EDITORIAL BOARD</b> | Henry J. Lee, MD, PhD<br>Henry W. Lim, MD<br>Insoo Kang, MD<br>Dean M. Hashimoto, MD, JD<br>Myung Hwan Kim, MD, PhD<br>Wan-Mo Kang, JD<br>Jongtae Yoon, MD, PhD<br>Sara Demy<br>David Y. Ko, MD<br>Han Choi, MD, LLM<br>Hyung-kwon Kim, MD<br>Joshua Berlin<br>Laura Carabello<br>Mark Paxton, JD, MS<br>Querida Anderson<br>Kimberly Ha<br>Sundeep Lal, PhD, MBA<br>Yiqin Shen<br>Vincent Liu<br>Les Funtleyder, MPH<br>Sabina Lee<br>Mario Pennisi | Weill Cornell Medicine<br>Henry Ford Health System<br>Yale School of Medicine<br>Boston College Law School<br>Asan Medical Center<br>Fox Rothschild LLP<br>Korea University Medical Center<br>Demy-Colton<br>Loma Linda University<br>Oracle Investment Management<br>Sociedade Beneficente Israelita Hospital Albert Einstein<br>BioCentury<br>CPR Communications<br>Office of the Surgeon General of U.S. Army<br>BioPharm Insight<br>KKH Advisors<br>BioConnexUS<br>Mergermarket<br>Fosun Pharma<br>E Squared Capital Management<br>Obscure Ventures<br>Life Sciences Queensland |

**PUBLICATION** W MEDICAL STRATEGY GROUP

**EDITORIAL STAFF** Patrick Lee / James Bae / Sabina Lee / Hyo Jin Joo / John Oh / Ji Soo Yoon

**MAIN OFFICE** 440 Sylvan Ave. Tel. 201.408.5342  
 Englewood Cliffs, NJ 07632 Email. wgroup@wmedical.org

**MEDIA PARTNERS**



**BioCentury**

World Asian Medical Journal is published bi-monthly by W Medical Strategy Group, 440 Sylvan Ave., Englewood Cliffs, NJ 07632. Tel. 201.408.5342, Email. wgroup@wmedical.org, Website www.wamj.org. Please send inquiries, subscription requests and address changes to the above address. Entire contents of this magazine are protected by copyright ©2020 WAMJ and may not be reproduced in whole or in part without express written consent. All rights reserved.

**SCTF**

Stomach Cancer Task Force

# Gastric Cancer Disparity in the US: *A Threat to Racial and Ethnic Minorities*

May 7th, 2024 (Tuesday)

11:30 AM - 1:30 PM

**Cannon House Office Building**

27 Independence Ave SE

Washington, DC 20003

Hosted by

**NEW YORK**  
Health Forum

Supported by

**SCL**  
Global Healthcare  
SCL GROUP

**CVH**  
Center for Viral Hepatitis

**KHIDI**  
Korea Health Industry  
Development Institute

**WAMJ**  
World Asian Medical Journal

**KAAGNY**

**HOPE FOR  
STOMACH  
CANCER**

## Table Of Contents

- 05 Our Editorial Boards
- 07 Table Of Contents
- 08 From The Publisher
- 09 From The Editor-In-Chief
- 11 WAMJ Recap Of The Last Issue
- 14 Cover Story  
Inspirational Asian Healthcare Leader  
Kyoung Ryul Lee, MD, PhD  
CEO of the SCL Group, a Specialist in Laboratory  
Medicine
- 23 Special Report I  
Innovation and Equity discussed at 24th New York  
Health Forum
- 26 Special Report II  
Prestigious Health Equity Award presented by  
New York Health Forum
- 32 Healthcare Industry Report  
FemTech Supports Women in the Workforce
- 40 Conference Alerts
- 44 Latest Healthcare Industry News



### Cover Story

Inspirational Asian Healthcare Leader  
Kyoung Ryul Lee, MD, PhD  
CEO of the SCL Group, a Specialist in Laboratory Medicine



### Special Report

- I Innovation and Equity discussed at 24th New York Health Forum
- II Prestigious Health Equity Award presented by New York Health Forum



### Healthcare Industry Report

FemTech Supports Women in the Workforce



## From the Publisher

**Chul S. Hyun, MD, PhD, MPH**

Publisher  
President, Center for Viral Hepatitis  
Chairman, New York Health Forum  
Founder, Stomach Cancer Task Force

Welcome to the 29th edition of the World Asian Medical Journal (WAMJ). This year marks the 10th anniversary of WAMJ, which was first published in March 2014 as WKMJ. This milestone would not have been achievable without the dedication and hard work of many individuals, including sponsors, readers, and others who participated in various ways. I am especially thankful to Dr. Dohyun Cho, his team, and Drs. Joe McMenamin and David Ko for their exceptional leadership and contributions.

WAMJ and the New York Health Forum (NYHF), held quarterly, are our primary communication channels for fostering innovation, education, and entrepreneurship in medicine and bio-health. They serve as platforms for initiating dialogues on crucial healthcare issues. Over the past decade, we have covered a wide range of medical topics, industry discussions on new drugs and biotech, and health policy matters. WAMJ will continue to feature renowned physicians and bio-health key opinion leaders, along with highlights of top stories and cutting-edge trends in the healthcare industry. It provides excellent networking opportunities to connect with clinicians and industry professionals, establish relationships, and explore collaborations.

April is National Minority Health Month, a time to focus on the health disparities of racial and ethnic minorities in the United States. It aligns with the goal of WAMJ and NYHF to advance and champion health equity to improve today's healthcare. To achieve this goal, we have created the NYHF Health Equity Award, which specifically addresses disparities in health drivers, racism, bias, and structural flaws in the health system. As illustrated in the recap of the 24th NYHF in this issue, our annual award acknowledges individuals or organizations for their outstanding and transformative efforts to address health disparities, particularly those that are unacceptable and can be rectified.

We are thrilled to have Dr. Kyoung Ryul Lee as the first recipient of the NYHF Health Equity Award. Dr. Lee serves as the Chairman of the Seoul Clinical Laboratories group and is a founder of the Hanaro Medical Foundation, an organization that offers comprehensive health evaluations. With experience leading multiple medical institutions in Korea, China, Mongolia, and the CIS region, Dr. Lee is dedicated to developing innovative solutions and practices in preventive health to ensure access to affordable and adequate healthcare while reducing health disparities.

WAMJ is devoted to creating a supportive network for all healthcare professionals. The constantly evolving healthcare environment, coupled with a commitment to health equity, adds additional challenges to the clinical and biotech industry. WAMJ will assist us in extending our reach beyond the conventional confines of medicine and healthcare, enabling us to apply our expertise to a broader range of diversity. Happy Reading!



## From the Editor-in-Chief

**Joseph P. McMenamin, MD, JD, FCLM**

Editor in Chief  
EVP, W Medical Strategy Group  
Partner, Christian & Barton, LLP

Welcome, WAMJ readers, to this, our 29th edition. As is our custom, our cover story is an interview, yielding a brief biography, of a stellar Asian healthcare professional. Kyoung Ryul Lee, MD, PhD, Chairman, SCL Group, describes for us his education and training, including his difficult specialty selection decision. Happily for the field, Dr. Lee elected to become a laboratory medicine specialist, inspired by asking himself, "How can we assist doctors in minimizing errors and enhancing the precision of diagnoses and treatments?" From his career path, one infers that he continues to ask himself this question, and to develop new and better answers for it.

As our readers are aware, it is hard enough to master one field, never mind two. As he has demonstrated repeatedly, Dr. Lee has nevertheless managed to become both a skilled physician and an astute, successful businessman. Soon after completing his training, Dr. Lee was appointed a professor, teaching students. Later, he founded a venture start-up to develop drug discovery support services and disease diagnostics. After that, Dr. Lee joined the management ranks at SCL (Seoul Clinical Laboratories), Korea's first specialized laboratory agency. SCL Group has grown into a comprehensive medical platform company affiliated with multiple healthcare companies, including Hanaro Medical Foundation, a professional medical examination organization, SCL Healthcare, and Bio Food Lab. In his discussion, Dr. Lee points out that laboratory medicine's continuing relevance reflects, in part, its centrality to diagnosis and thus management of new infectious diseases, its importance to the growth of personalized medicine, and the recent integration of advanced technologies such as artificial intelligence (AI) into diagnostic tests and pathology. These cutting-edge developments provide new opportunities for laboratory medicine to augment its already invaluable contributions to health and healthcare.

Dr. Lee's achievements have not gone unrecognized. He is a professor of Laboratory Medicine at Yonsei University and director of the Global Village Welfare Foundation. He has been honored with the Minister of Health and Welfare Award, the Minister of Economy and Finance Award, and a series of other national and international prizes from several Asian countries. He seems to take particular delight in serving as the President of the Yonsei University Alumni organization, recognized as the #1 private university in Asia by QS, <https://www.topuniversities.com/university-rankings>, and by THE rankings, <https://www.timeshighereducation.com/world-university-rankings>.

We trust you'll enjoy reading Dr. Lee's interview, and we're excited to present additional engaging articles in our 29th edition. These include two Special Reports: one recapping the 24th New York Health Forum and another highlighting the prestigious Health Equity Award presented by the New York Health Forum. Additionally, we feature a health industry report on how FemTech supports women in the workforce within the healthcare industry. Happy Spring, and happy reading.

Please send inquiries and subscription requests to [wgroup@wmedical.org](mailto:wgroup@wmedical.org)

## WAMJ Recap of the Last Issue



### Cover Story

**Chi-Cheng Huang, MD, FACP, SHM**

**Executive Medical Director of General Medicine and Hospital Medicine Shared Services Wake Forest Baptist Health System**

Chi-Cheng Huang, Executive Medical Director of General Medicine and Hospital Medicine Shared Services at Wake Forest Baptist Health System, discusses his journey into medicine and his extensive experience working in various hospital settings. He chose a career in medicine with a focus on transcending socio-cultural boundaries in patient care. Dr. Huang emphasizes the critical roles of different hospital types, such as Critical Access Hospitals (CAHs) in rural health and Academic Medical Centers (AMCs) in medical innovation and education. As a founder of a non-profit organization aiding street children in Bolivia, Dr. Huang underscores the importance of community service and addressing health inequities. Dr. Huang's experiences highlight the transformative impact of healthcare and the imperative to cultivate a profound appreciation for the profession.

### Special Report I

**Chronic Hepatitis B(CHB) in the United States**

The prevalence of Chronic Hepatitis B (CHB) presents a significant public health challenge, particularly in the United States where an estimated 880,000 to 2.4 million individuals are chronically infected. Immigrant populations from countries with endemic HBV contribute substantially to these numbers. Recent CDC recommendations aim to improve screening by advocating for universal testing and expanding criteria beyond risk-based assessments. However, challenges persist, including underdiagnosis and inadequate access to care, especially among minority and immigrant communities. Initiatives focusing on community-level education and screening have shown promise in addressing barriers to diagnosis and treatment. Reevaluating antiviral treatment guidelines and fostering community-based approaches are crucial steps towards reducing the burden of CHB and advancing towards the UN's goal of viral hepatitis elimination by 2030.

### Biopharma Report I

**Blending Biology and AI: Dr. Markus Gershater on the Future of Life Sciences**

Dr. Markus Gershater, Co-founder and Chief Science Officer of Synthace, illuminates the profound impact of AI on the future of biotech, highlighting the promise of AI to unveil biological insights beyond current comprehension. He emphasizes the crucial need for a shift in scientific approaches to fully integrate AI into biological research, drawing parallels to historical technological transformations. Dr. Gershater envisions a future where AI enables the routine generation of vast, high-quality data sets that revolutionize our understanding and manipulation of biological systems. However, he underscores significant challenges, including data quality and complexity, requiring innovative approaches to experiment design and data management. Ultimately, Dr. Gershater envisions AI transforming our ability to interact with and comprehend biological systems, potentially leading to unprecedented scientific breakthroughs in the coming decade.

The 14<sup>th</sup> Global Healthcare & Medical Tourism Conference

# MEDICAL KOREA 2024

Connected Healthcare for All:  
A New Horizon beyond Barriers

March 14<sup>Thu</sup> - 15<sup>Fri</sup>, 2024  
Conference Room (3~4F), COEX

Hosted by



Organized by

**khidi** Korea Health Industry  
Development Institute



## Innovation, Quality, Safety

Pioneer in Global  
Ophthalmic Medical Device

Founded by leading ophthalmologists in Korea, Oculight is a medical device company dedicated to developing innovative ophthalmic devices.

The Nam Illumination Chopper was developed to prioritize patient safety by making Cataract surgeries safer and easier. Oculight promises to promote patient care through people and technology and to remain the leading company in ophthalmic devices.



### The Nam Illumination Chopper – Innovation in Cataract Surgery

The Nam Illumination Chopper delivers patient safety, surgical efficiency, and quality results in Cataract surgery.

[www.oculight.co.kr](http://www.oculight.co.kr)  
[oculight@oculight.co.kr](mailto:oculight@oculight.co.kr)  
201.245.7349





Inspirational Asian  
Healthcare Leader

**Kyoung Ryul Lee, MD, PhD**

CEO of the SCL Group, a Specialist in Laboratory Medicine

1. What motivated your decision to attend medical school and become a physician? Could you share some particularly challenging or memorable incidents from your career in medicine?

I think I've been trying to help people with disabilities or suffering from diseases since childhood. From adolescence, I realized that I wanted to heal the underserved and marginalized through a career as a physician, where I could treat diseases in earnest.

Going into medical school, every step of the way was challenging, but deciding on a specialty was probably the most difficult choice I had to make. Even today, many people still find laboratory medicine unfamiliar. This was even more evident in the 1980s when the public perception of a doctor primarily revolved around patient care, spanning various specialties such as internal medicine, pediatrics, obstetrics, gynecology, or surgery, with limited understanding of laboratory medicine.

Because of this lack of familiarity, laboratory medicine became the focus of my thoughts since my days as a medical student: "How can we assist doctors in minimizing errors and enhancing the precision of diagnoses and treatments?" Although it was not a well-known study at the time, I had a vision for the future of laboratory medicine in that it serves as the foundation for doctors to make decisions to save people. This choice has greatly impacted who I am today and the development of SCL.

2. Your instrumental role in the development and expansion of one of Korea's most renowned medical examination centers, along with the establishment of facilities for diagnostic reagents and testing laboratories, is commendable. As a visionary in the global medical arena, could you please elaborate on your business philosophies and strategies?

Laboratory Medicine is a field dedicated to aiding doctors in achieving the objectives of patients and healthcare providers by providing error-free treatment. It emphasizes evidence-based medicine (EBM) to acknowledge and effectively utilize this importance.

During my internship and residency in laboratory medicine in the late 1980s and 1990s, I witnessed with interest that EBM became increasingly established in the medical community and expanded globally, and changed the medical industry. It was during this period that I envisioned crafting a world where both patients and healthcare providers find fulfillment through the implementation of evidence-based medicine (EBM). I became a specialist in laboratory medicine and was appointed a professor, and taught students. Then, I started a venture start-up to develop drug discovery support services and disease diagnostics. Afterward, I became involved in managing SCL, Korea's first specialized laboratory agency, with the ambition of creating a professional medical service organization.

I believe it's essential for a company to have a clear vision for development and growth. Since medical



school, I've been constantly observing the domestic and international medical scene, identifying overlooked opportunities, and transforming them into visionary pursuits that others may not have recognized. Only when leaders have a clear vision, can they articulate it succinctly and clearly to their employees, and if the CEO isn't convinced, they can neither lead nor grow.

**3. Your impressive transition from an influential physician to a successful CEO and chairman of a group of multi-business entities is noteworthy. As someone with experience in both healthcare and corporate leadership, what are your future aspirations and plans?**

Starting with the establishment of SCL (Seoul Clinical Laboratories) in 1983, which specialized in testing, SCL Group has grown into a comprehensive medical platform company with multiple affiliated companies in the healthcare sector, such as Hanaro Medical Foundation, a professional medical examination organization, SCL Healthcare, and Bio Food Lab.

In particular, SCL Group strives to expand its overseas business to promote 'K-medicine' to the world and strengthen its global competitiveness. Each of the group's affiliates aims to expand overseas and eventually establish themselves in developed countries such as the United States and Europe. To date, we have entered Mongolia (MOBIO) and China

(Dian Lab) through a close network of affiliates and recently established K-Lab in Indonesia to accelerate our expansion into overseas markets based on our long-standing research and analysis capabilities.

**4. As an eminent opinion leader in laboratory medicine, could you highlight major changes or emerging trends in this field? Additionally, how do you foresee the field evolving in the next five years?**

The significance of laboratory medicine has heightened alongside the prevalence of new infectious diseases and the advancement of personalized medicine, which analyzes patient characteristics to prevent and treat illnesses. Furthermore, with the recent integration of advanced technologies such as artificial intelligence (AI) into diagnostic tests and pathology, laboratory medicine has emerged as a robust growth engine within the digital healthcare industry.

The COVID-19 pandemic, especially in the last few years, has shown us that fast and accurate diagnosis is critical for patients and healthcare systems. I believe that diagnostic testing methods will continue to improve, and the role of the laboratory medicine specialists will be emphasized to ensure the reliability of the various types of results. Standardization and harmonization of test methods must be supported to obtain reliable data. Therefore, I believe that the role of specialists in laboratory medicine and testing medical institutions is very important to keep up with the development of various diagnostic technologies.

While data utilization and security remain challenges for real-world applications, the use of digital tools in healthcare is on the rise. Countries are beginning to accelerate their adoption and include them in their healthcare systems.

Diagnostic test data plays a pivotal role in medical decision-making, as errors in this data can significantly affect the accuracy of diagnoses and subsequent treatments. Ensuring the provision of high-quality

data is therefore paramount in healthcare. Additionally, companies in the healthcare sector leveraging big data and digital technologies to produce diverse medical information stand to gain a competitive edge in the global healthcare market.

**5. Your contributions to Yonsei University, where you currently serve as the President of the Yonsei University Alumni organization, are significant. What is your vision for Yonsei University and the Alumni Association, and how do you see their roles evolving?**

Founded in 1885, the philosophy of Yonsei University has always been to "cultivate leaders who internalize the spirit of truth and freedom." The modern world doesn't just need one kind of knowledge. Instead, it needs people who can converge and apply diverse knowledge to solve problems through creative

thinking. Under the slogan "Promise Yonsei, Challenge Yonsei!", the 31st Alumni Association strives to promote fellowship and harmony among alumni and to develop Yonsei and its alumni with its three priorities below.

First, we are committed to respecting diversity and uniting under the name of Yonsei, as the Alumni Association comprises various alumni from undergraduate, graduate, and special programs.

Second, we are focused on expanding our development fund. The world's top universities boast vibrant cultures of philanthropy. It's a source of pride and admiration that Yonsei, my alma mater, has been recognized as the #1 private university in Asia by QS and THE rankings. However, to propel ourselves into the ranks of the top 30 universities worldwide, establishing a robust development fund is paramount. Securing a stable development fund will be essential for the university to



Dr. Lee presents his speech during the international symposium marking the 40th anniversary of SCL.



# TOTAL HEALTHCARE SOLUTION FOR ALL

Healthcare innovation since 1965

## ABOUT US

Huons Group is a leading pharmaceutical company headquartered in South Korea. Huons Group operates 11 subsidiaries, including four companies listed on the KOSDAQ exchange. Huons USA, located in California, serves as the primary sales force for the company in the United States region.

## OUR PRODUCTS

Huons Group operates 13 manufacturing facilities across Korea, China, and Vietnam, exporting a diverse range of products to over 30 countries worldwide, including pharmaceuticals, cosmetics & aesthetics, medical devices, nutritional supplements, and foods.



- INJECTABLES**  
Actively supplying FDA-approved products to the US market.
- 1% and 2% Lidocaine HCl Injection - 5ml Vial
  - 0.75% Bupivacaine Injection in 8.75% Dextrose - 2ml Ampule
  - 1% Lidocaine HCl Injection / 5ml Ampule
  - 0.9% Sodium Chloride Solution - 10ml Ampule



**MEDICAL DEVICES**  
Introducing lithotripsy, and aesthetic devices in the US market.



**NUTRITIONAL SUPPLEMENTS**  
Actively promoting a wide range of unique nutritional supplements.



## COVER STORY

develop into a globally renowned research institution that will attract esteemed professors and the finest students from around the world.

Lastly, we are committed to discovering future talents with convergence capabilities. As I mentioned earlier, the modern world doesn't just need one kind of knowledge. Instead, it demands individuals who can integrate and apply diverse knowledge to address challenges with innovative solutions. Leveraging the breadth of majors offered by the university, we will facilitate collaborative education across disciplines to foster the development of these interdisciplinary talents who will shape the future.

One of our elderly founders, Missionary Horace G. Underwood, founded Yonhee and named it 'Chosun Christian College,' signifying it as the university of God's choice. Yonsei University will take on the challenge with this profound commitment on our journey forward.

### 6. Our readers of the World Asian Medical Journal include physicians and leaders in the health and medical care industry throughout

### the U.S. and other countries. As an entrepreneur and thought leader in the medical field, what insights or messages would you like to share with our audience?

Since the Black Death in the Middle Ages in 1350, when the global population stood at approximately 370 million, the world has experienced moderate population growth. However, the Age of Exploration, the Industrial Revolution, and advancements in science and technology have spurred rapid population expansion, with the global population surpassing 8 billion in 2022.

As 'high calories & low nutrition' foods were introduced to serve the needs of this growing population, various lifestyle diseases such as hypertension, diabetes, dementia, and cancer have become increasingly prevalent. To address this global problem, the World Health Organization is making great efforts to strengthen the prevention of diseases by advocating sustained lifestyle improvements. Therefore, healthcare providers around the world should unite and concentrate their efforts on raising public awareness and promoting healthier lifestyles.



**Kyoung Ryul Lee, MD, PhD**  
CEO of the SCL Group, a specialist in laboratory medicine

Dr. Lee graduated from the College of Medicine and Graduate School of Yonsei University, envisioning evidence-based medicine (EBM) during his studies. While working as a professor in the Department of Laboratory Medicine at Yonsei University, he founded a start-up company and became SCL's second CEO, elevating it into a leading laboratory specialist with world-class research capabilities. With his leadership, SCL is taking another leap forward as a comprehensive healthcare group that provides transparent, data-driven precision medicine and digital healthcare platforms. In addition to his professional endeavors, Dr. Lee embodies a commitment to philanthropy, actively engaged in various social contribution activities such as health promotion projects, sharing daily necessities and IT education projects for the underprivileged in the local community, improving the medical environment overseas, and providing essential medical supplies to disaster-stricken areas. Alongside his leadership roles as the CEO of SCL Healthcare, president of SCL and CEO of InnoTherapy, he holds esteemed positions in multiple organizations, leveraging his expertise for broader societal impact, such as president of Yonsei University Alumni Association, professor of Laboratory Medicine at Yonsei University and director of the Global Village Welfare Foundation. His exceptional contributions have garnered widespread recognition, including receiving the Minister of Health and Welfare Award, Minister of Economy and Finance Award, Order of the Polar Star from the president of Mongolia, Mongolia's Medical Pioneer Medal, Health Industry Development Special Advisor Award from China and Korea's National Brand Grand Prize.



ysyoon@huonsusa.com  
birdie84@huonsusa.com  
www.huonsusa.com



Huons USA Office  
200 Spectrum Center Drive,  
Suite 4036, Irvine, CA 92618


# Special Report

## SPECIAL REPORT I

Innovation and Equity discussed at 24th New York Health Forum

## SPECIAL REPORT II

Prestigious Health Equity Award presented by New York Health Forum



Stepping out to a healthier tomorrow

# The **value** of being **'together'** Trust for a better world



- Diagnostic Laboratory Services
- Diagnostic Pathology
- Functional Medicine
- Molecular Diagnosis
- Special Chemistry
- R&D Innovation Center
- Medical Device Clinical Trial Center
- BioBank
- Medical Checkup Center

Tel | 1800-0119  
Website | [www.scllab.co.kr](http://www.scllab.co.kr)

# Innovation and Equity discussed at 24th New York Health Forum

BY **DOHYUN CHO, PHD**, MANAGING EDITOR

The 24th conference of the New York Health Forum unfolded on March 28, 2024 with an air of anticipation, drawing together a diverse array of healthcare stakeholders, thought leaders, and experts under one roof at the Korea Society, New York City. Organized by W Medical Strategy Group, the event served as a catalyst for robust discussions, knowledge sharing, and advocacy in the realms of healthcare innovation and equity.

The proceedings commenced with an auspicious opening session helmed by DoHyun Cho, who welcomed attendees with warmth and enthusiasm. Chul S. Hyun, Chairman of New York Health Forum, and Soonmahn Park, U.S. representative of Korean government agency named Korea Health Industry Development Institute, lent their esteemed presence, setting the tone for the day's deliberations. The highlight of the session undoubtedly came in the form of Jamie Metzl's keynote address. As a renowned technology and healthcare futurist, Metzl's insights into the "Technological Revolution and the Future of Healthcare" left the audience inspired. Drawing from his rich experience and expertise, Metzl painted a vivid picture of the transformative potential of emerging technologies in shaping the healthcare landscape of tomorrow. Expounding upon the convergence of artificial intelligence, genomics, and digital health,

Metzl underscored the need for proactive adaptation to harness the full potential of these innovations. Jamie envisioned a future where technology would not only augment clinical care but also democratize access to healthcare on a global scale.

The first substantive session of the day, moderated by Sabina Lee, a senior consultant at W Medical Strategy Group dealt with the intricacies of the life sciences and healthcare sector. Esteemed panelists including Jay Olson of investment bank Oppenheimer and Co., Mary Howard from a New York City based business accelerator ELabNYC, Mark Paxton, a regulatory legal counsel from Brown Rudnick, LLP, and Jung Kug Lee from KHIDI USA took center stage, sharing their wealth of knowledge and experience with the eager audience. From investment trends to technological innovations and entrepreneurial endeavors, the panelists talked about key items in dissecting the myriad facets of the healthcare industry. Their insights underscored the pivotal role of innovation and collaboration in driving progress and addressing the evolving challenges confronting the sector.

Olson, drawing from his extensive experience in equity research and finance, highlighted the importance of strategic investments in driving innovation and growth within the biotech and pharmaceutical sectors.

Howard, a seasoned entrepreneur and advocate for biosciences commercialization, emphasized the role of incubators and accelerators in nurturing early-stage ventures and fostering a culture of entrepreneurship. Paxton, with his expertise in FDA regulatory matters, shed light on the complexities of navigating regulatory frameworks and compliance requirements in an increasingly globalized pharmaceutical landscape. Meanwhile, Lee, representing KHIDI USA, offered insights into the burgeoning opportunities for cross-border collaboration and market entry between the US and South Korea.

With a renewed focus on health equity in the wake of the COVID-19 pandemic, the second session of the forum took on added significance. Kyoung Ryul Lee, Chairman of SCL Group, was honored with the inaugural Health Equity Award for his tireless efforts in advancing equal access to healthcare. Although unable to attend in person, Dr. Lee's impactful work was acknowledged and celebrated through a poignant video acceptance speech. Subsequent presentations by Levi Waldron, a professor at CUNY graduate school of public health, and Chul S. Hyun, founder of Center for Viral Hepatitis, further enriched the dialogue, shedding light on the roles of data science and ethnic disparities in healthcare, respectively. Their incisive analyses and impassioned advocacy served well to



## SPECIAL REPORT I

address inequities and ensure equitable healthcare for all. Waldron, an esteemed epidemiologist and biostatistician, elucidated the transformative potential of data science in identifying and addressing health disparities. Drawing from his research and academic endeavors, Waldron highlighted the need for robust data infrastructure and interdisciplinary collaboration to harness the power of big data in driving evidence-based interventions and policy reforms. Hyun, a distinguished physician and author, offered a poignant reflection on the enduring challenges of ethnic disparities in healthcare. From linguistic and cultural barriers to systemic inequities in access and quality of care, Hyun underscored the imperative of culturally competent healthcare delivery and community engagement in bridging the gap.

Before closing the 24th New York Health Forum, attendees were treated with a comprehensive overview of the remarkable journey undertaken by W Medical Strategy Group, the hosting organization of this forum over the past ten years. Founded with a vision to pioneer excellence and foster collaboration between Korea and the US in the healthcare sector, the organization has left an indelible mark on the

industry landscape. From its inception in 2014, W Medical Strategy Group has navigated cross-border collaboration with unparalleled expertise. With a mission to be the "First Mover & Best Connector to Improve Human Health," the organization has spearheaded hundreds of projects, generated billions of transactional values and engaging with thousands of key opinion leaders. Through its diverse portfolio of initiatives, including the World Asian Medical Journal and the New York Health Forum, W Medical Strategy Group has emerged as a catalyst for innovation and dialogue, facilitating meaningful exchanges among healthcare professionals worldwide. As it embarks on its next chapter, marked by multiple innovative initiatives, W Medical Strategy Group remains steadfast in its commitment to advancing health and wellness for all.

In sum, the 24th New York Health Forum galvanized stakeholders of a wide healthcare spectrum to chart a course towards a more equitable, innovative, and sustainable future. As the echoes of the forum reverberate far and wide, one thing remains abundantly clear: the journey towards transformative change in healthcare has only just begun.



### Dohyun Cho, PhD

CEO, W Medical Strategy Group  
President, New York Health Forum

DoHyun Cho is the founder, president, and CEO of a U.S. consulting company W Medical Strategy Group. W Medical Strategy Group has subsidiaries including World Asian Medical Journal, New York Health Forum, W MediTech, and Green Alley. He also serves as the board member for several companies. Prior to his current position, he served as the Head of Korea Health Industry Development Institute (KHIDI) USA in New York for six years, a specialized agency of the Ministry of Health of South Korea. He also served as a Board of Director for Korean American Chamber of Commerce and serving as the Advisory Member for the Asia-Pacific Economic Cooperation (APEC) Harmonization Center, Korean government delegate for APEC Life Science Working Group, Healthcare division representative for Korea-U.S. Business Council, etc.

# KoMEDus

Korean Medical Device Committee in the U.S.

## Better Service Better Life

KoMEDus will support Korean medical device companies as they enter the US Market.

### OUR MISSION

KoMEDus aims to establish a platform for communication and cooperation between American and Korean medical device companies, ultimately creating a strong and reliable network. We strives to serve as the bridge in the healthcare industry between Korea and the United States. KoMEDus encourages the healthcare industry and medical device companies in their efforts to enhance both service and quality of life.

**KoMEDus is organized and operated by KHIDI USA**

### PARTICIPATION COMPANIES



Contact KHIDI USA (Jung Kug Lee, jcl4ever@khidiusa.org)

# Prestigious Health Equity Award presented by New York Health Forum

BY WAMJ EDITORIAL TEAM



## What is the NYHF Health Equity Award?

Health disparity has existed universally throughout civilizations since the time of Hippocrates of Kos, the father of modern medicine. The post-COVID-19 pandemic world has revealed deepening disease disparities in the US healthcare system and worldwide more than ever. This urgent issue has become a critical socio-political factor affecting the well-being of the public, a major concern to be addressed by healthcare leaders and politicians globally.

Equal access to healthcare builds healthy individuals and a strong foundation for a thriving society. Reducing healthcare disparities is a monumental task that requires stakeholders from the healthcare industry, government, and community organizations, along with dedicated individuals, to work together.

With this belief, the NYHF Awards recognizes and celebrates outstanding efforts made by individuals or organizations in this regard. It promotes the work of healthcare pioneers, both organizations and individuals, whose mission and practices have made a difference in reducing health disparities in the United States and the world. The award is administered by the NYHF Award Committee.

## A. Background

NYHF has brought together since 2014 trailblazing healthcare professionals and leadership that are serving the unique needs of diverse communities of New York City and beyond.

The NYHF Award Committee is designed to create a thorough, informed, and well-balanced decision-making process. The NYHF Award Committee identifies and recommends the most deserving candidates and has the responsibility of making the final decision and formally awarding the prizes. This procedure helps uphold the integrity and credibility of the NYHF Awards.

## B. Why New York?

The selection of New York City as the home for the Health Equity Award is a strategic decision aimed at leveraging the city's diverse ecosystem, healthcare innovation, networking opportunities, symbolic significance, and global accessibility to maximize the impact and influence of the award on the promotion of health equity.

New York City stands as a global symbol of diversity, with a rich tapestry of cultures, backgrounds, and experiences. Health Equity Awards aim to emphasize

the importance of inclusivity and recognize the city's commitment to fostering an environment that celebrates diversity in healthcare and beyond. Also, the city is renowned for being at the forefront of healthcare innovation, housing world-class medical institutions, research facilities, and a vibrant community of healthcare professionals. Placing the Health Equity Award in New York City aligns with our vision to promote and acknowledge groundbreaking initiatives in health equity that emerge from this epicenter of innovation.

## Mission & Purpose

The award's mission is to

- Celebrate the work of individuals in their effort to reduce health disparities in healthcare and communities.
- Increase awareness of innovative solutions and practices for health care equity to ensure access to health care for all, including those in the margins of society.
- Reduce existing disparities in the immigrant communities.
- Encourage medical practitioners, politicians, organizations and companies to actively engage and address the issues of global health disparities.

## Committee

NYHF Award Committee is composed of 24 key opinion leaders of healthcare, life sciences and public health. NYHF Award Committee is led by the chairman Chul S. Hyun, MD, PhD, MPH

## Categories

The NYF Health Equity Awards are awarded in two categories which are Health Equity Award and Health Equity Contribution Prize. Each prize has its own selection criteria and standards to evaluate and same NYHF Award Committee will evaluate the nominations and select the recipients.

## A. NYHF Health Equity Award

NYHF Health Equity Award is the Grand Prix of NYHF Awards. This Award is a prestigious recognition established to honor and celebrate the remarkable contributions of an individual who has demonstrated exceptional dedication to enhancing health equity across diverse domains. This singular award is bestowed upon an outstanding figure whose influence extends across research, community engagement, policy implementation, and various other fields contributing to the advancement of health equity on a broad scale.

**B. Health Equity Contribution Prize**

Complementing the prestigious NYHF Health Equity Award, Health Equity Contribution Prizes are a series of five individual recognitions designed to honor those who have made significant contributions to advancing health equity in diverse spheres. These awards aim to celebrate the collective impact of individuals who, through their dedicated efforts, have

positively influenced health outcomes and promoted inclusivity within various aspects of healthcare. Categories of the Health Equity Contribution Prizes can be given to individuals in the fields of Innovations in Healthcare Access, Community-Based Initiatives, Advocacy in Health Policy, Youth and Student Advocacy, Collaborative Partnerships for Health Equity and etc.

**Application Process and Eligibility**

- Eligibility: Exceptional individuals who contributed in advancing health disparity science and minority health.
- Individuals who has impactful public health careers and records.
- Application deadline: every December 31st

**Selection Criteria**

- **Performance** including work factors such as quality, productivity, timeliness, cost reduction, or improved service to the public
- **Actions** including special projects, overcoming unusual or difficult circumstances, or problem-solving using extraordinary methods or insight
- **Inspirational initiatives** in developing new approaches or procedures, innovations that improve effectiveness, creative work on a specific project, efforts beyond the call of duty and beyond the scope of the position.

**Timeline**

- October 1:** Call for nominations announced in NYHF Update
- December 31:** Nomination forms due
- January ~ February:** Board review of nominations complete
- March 1:** Honoree announced in NYHF Update
- March~April:** Award presented to honoree during the NYHF Conference



The first awardee, Dr. Kyoung Ryul Lee, and his video acceptance speech at New York Health Forum



Dr. Hyun presenting the first Health Equity Award at New York Health Forum.

# CVH

## Center for Viral Hepatitis

바이러스간염진료센터

- ✓ **To promote the awareness of hepatitis B**
- ✓ **To screen in high risk population**
- ✓ **To facilitate the linkage to care**



[www.cureHep.org](http://www.cureHep.org)

# Healthcare Industry Report

**NEW YORK**  
Health Forum

NYHF is a gathering of influential individuals of the healthcare industry, during which attendees discuss significant industry topics including newly arising issues around the world.

[www.nyhealthforum.net](http://www.nyhealthforum.net) [wgroup@wmedical.org](mailto:wgroup@wmedical.org)



WAMJ is a magazine featuring renowned physicians and industry key opinion leaders, along with highlights of top stories and cutting-edge trends in the healthcare industry.

**WAMJ**  
World Asian Medical Journal

[www.wamj.org](http://www.wamj.org) [wgroup@wmedical.org](mailto:wgroup@wmedical.org)



# FemTech Solutions Support Women's Health in the Workplace

BY LAURA CARABELLO

While the term FemTech may be unfamiliar to some, there is wide and growing recognition among self-insured employers that are joining the legions of supporters who champion the adoption of FemTech solutions: diagnostic tools, products, services, wearables and software that use technology to address women's health issues, including menstrual health, fertility/reproductive health, pelvic and sexual health, contraception, maternal health, behavioral health and menopause.

First coined by Danish entrepreneur Ida Tin in 2016, FemTech industry trackers estimate the market size to be in the billions and overall interest in the sector is on the rise. Erin Weenum, chief strategist, Employee Benefits, Leavitt Great West Insurance, is quite familiar with the term and like most benefits consultants, she says there is increased interest and demand from employers looking to integrate these solutions.

"Speaking on behalf of employer groups that I advise, I see a combination of solutions being offered," says Weenum. "The most common focus has been on health plan coverage of infertility treatments. There are many creative ways to do this, from simply implementing standardized coverages to renegotiating the cost of in vitro fertilization (IVF) cycles with certain providers. Employers are increasingly identifying ways to support working parents: flexible work schedules, postpartum mental health resources, on-site childcare, eldercare, and breast milk donation, storage and shipping."

FemTech is a term that also encompasses products that address general health conditions that affect more women than men or affect them differently than they affect men, such as osteoporosis or cardiovascular disease. The sector spans all innovations designed to solve health concerns suffered solely, differently or disproportionately by women – covering everything from health during pregnancy and menopause to Alzheimer's and HIV.



Dani Kimlinger, CEO, MINES and Associates characterizes FemTech as incredibly important to address the unique needs of women," adding, "Personally, I appreciate FemTech as a consumer in a number of ways. My smart watch tracks a variety of important data points such as

the woman's menstrual cycle and offers information such as when is an optimal time to try for pregnancy -- as well as optimal times for endurance exercise."

Through her organization, FemTech solutions are part of their Employee Assistance Programs. As an example, they offer virtual lactation coaching and parenting coaching as well access to virtual points to counseling, such as therapists who are sensitive to the needs of women.

"We also offer a variety of FemTech support to our employees such as: virtual parenting and lactation

coaching, digital therapy and psychiatry, and mindfulness services as well as anonymous 24/7 peer support," she continues. "Through our health plan, smart watches with hormone tracking provide enrollees in our health plan to "work off" an Apple Watch through steps, exercise, and movement."



From the FemTech perspective, David Adamson, MD, FRCS, FACOG, FACS, reproductive endocrinologist, surgeon, founder and CEO of ARC Fertility, shares, "Empowering women in the workforce through FemTech is paramount for both individual well-being and organizational success.

Fertility and family-forming are a cornerstone of FemTech solutions designed to address various aspects of women's health – from pregnancy and postpartum support to resources for menopause. FemTech plays a crucial role in supporting women at every stage of their professional and personal journeys."

For self-insured employers, Dr. Adamson advises that by offering comprehensive FemTech support, companies not only enhance employee well-being but also contribute significantly to recruitment and retention efforts.


"By fostering a supportive environment that prioritizes women's health, organizations can attract and retain top talent, creating a workplace that values inclusion of a chosen lifestyle. "Any tool or service offered by an employer that gives women better insight to their wellbeing can positively impact recruitment and retention rates, contributes Diane Deinhart, VP, strategic partnerships, Nova Healthcare Administrators.



"For employers looking for ways to provide more holistic

and inclusive benefits, tools or technology to support women's health, a FemTech solution is a great place to start," says Deinhart. "It is my understanding that FemTech empowers women to take greater control of their health by providing access to personalized health information and resources. In turn, this technology helps women to track their symptoms over time, identify patterns and potential health issues so they make more informed decisions, resulting in better health outcomes."

She says that by prioritizing the unique needs and experiences of women, employers who incorporate FemTech into their health benefits may significantly impact the health and wellbeing of female employees, thereby creating a more supportive and inclusive workplace culture.



Brittany Barreto, PhD, CEO, FemHealth Insights observes that employer-supported models have become increasingly popular, noting, "Women make up approximately half of the workforce and the majority of women's working years are spent during their reproductive and menopausal

stages."She cites the company Milk Stork as an example of a company to help breastfeeding mothers in the workplace by contracting with employers to help women ship their breast milk when they are traveling for work: "These unique solutions provide ways for employers to support their workforce by meeting employees where they are at and supporting an employee's full wellbeing."

Dr. Barreto explains that while FemTech support was traditionally limited to just big tech and Fortune 100 companies, "We are now seeing the tides change with millions of lives covered through their employer supported programs. You now see academic institutions, insurance companies, and even auto manufacturers, starting to show up for their employees by offering coverage through major players in the FemTech industry. Benefits to employees include more holistic medical coverage for all of life's stressors (not just preventive care), and benefits to employers include greater productivity, a more engaged workforce and lower medical costs in the long run."

At Spring Consulting Group, they are familiar with FemTech and help clients assess a wide range of point solutions. Teri Weber, MBA, PMP, GBA, ICCIE, senior vice president, Spring Consulting Group, An Alera Group Company, LLC, says, "This includes those in the FemTech space and related fertility and women's health

solutions. The market continues to expand and there is an increasing interest from employers to invest in related services for their female workforce."

**Importance of Professional Guidelines in Reproductive Medicine**

When it comes to reproductive care, employers should ascertain that physicians participating in their contracted FemTech solution are adhering to the professional guidelines in fertility care. There are two prominent US-based organizations that establish practice guidelines, laboratory guidelines and ethics guidelines:

The American Society for Reproductive Medicine is dedicated to advancing the science and practice of reproductive medicine. The Society accomplishes its mission by pursuing excellence in evidence-based, life-long education and learning, growing and supporting innovative research, developing and disseminating the highest ethical and quality standards in patient care, and advocating for physicians and affiliated health providers and their patients. <https://www.asrm.org/about-us/>

Society for Assisted Reproductive Technology is the primary organization of professionals dedicated to the practice of In Vitro Fertilization (IVF) or assisted reproductive technology. The organization represents the majority of the ART clinics in the US. This mission of SART is to establish and maintain standards for ART so that people receive the highest level of care. <https://www.sart.org/>

As past president of both ASRM and SART, Dr. Adamson notes, "There's a lot of evidence out there that has to be considered -- some of which is better than others. While the development of guidelines is difficult, they're really, really important because they do help both physicians and patients do the right thing. It's important that guidelines are used when making medical decisions."

He says the most important aspect of guidelines is that people who are very knowledgeable about the field do a very extensive research of the literature, and all who are involved have to be unbiased and disclose any potential conflicts of interest that are assessed.

"The result is that people who are really committed to the best possible care and who are knowledgeable about the evidence are developing the guidelines as state-of-the-art, fact-based information," he continues. "The caveat to employers is this: unfortunately, some sources without much knowledge are putting out opinions as well as others who are quite knowledgeable but who

have commercial interests or other reasons are offering perspectives that may not be completely unbiased and may not take a really objective look at the evidence. Guidelines that come from these two organizations should instill confidence."

**Effectively Addressing Women's Health Status**


McKinsey & Company advises that women spend more of their lives in poor health and with degrees of disability -- the "health span" rather than the "life span." According to their recent report, a woman will spend an average of nine years in poor health, which affects her ability to be present and/or productive at home or in the workforce.

This report defines women's health as covering both sex-specific conditions, for example, endometriosis and menopause and general health conditions that may affect women differently than men. Relevant to employers, they say women are most likely to be affected by a sex-specific condition between the ages of 15 and 50, but nearly half of the health burden affects women in their working years. The issue of health equity is also important, encompassing access to the interventions and options that are right for each individual, regardless of their gender, sex, sexual identity, sexual orientation, age, race, ethnicity, religion, disability, education, income level, or any other distinguishing characteristic. For women, this can start with a better understanding of and access to interventions that lead to the best outcomes.

**Wide Range of FemTech Companies**

In addition to fertility-focused organizations, there are several unique FemTech companies:

- Elvie is the company behind an electric breast pump that slips inside a wearer's bra and lets them gather breast milk wherever they are. The device is also wirelessly controlled through a smartphone app.
- NextGen Jane is taking a health-focused approach with its smart tampons. There have been various efforts to develop improved tampons over the years by focusing on things such as comfort, absorbency and ease of use. However, these products will look for signs of health problems within the cells of a user's endometrial lining during her period.
- Gabbi is the developer of a healthcare software that accurately and inclusively predict a woman's risk for breast cancer and equips her to take action with community support. The Gabbi Risk Assessment Model uses AI to predict a woman's two-year risk of breast cancer and is used to create a personalized action plan.
- Work & Mother provides a network of fully equipped lactation facilities that support working moms and make it easier for employers to comply with FLSA regulations. Work & Mother's suites have everything



needed to pump during the workday, including private rooms, hospital-grade pumps and accessories, fridges, storage, a private booking system and more.

- Lattice Medical is an implantable medical device company that develops and manufactures breakthrough technologies for post-cancer breast reconstruction. While silicon implants bear long-term risks and autologous surgeries require several invasive surgeries, Lattice Medical offers a bioabsorbable, tissue-generated implant that allows for natural reconstruction by regenerating in a single, hour-and-a-half-long surgery. Once regenerated, the implant slowly disappears for full reabsorption over 18 months and the patient recovers with a full breast with their own tissue.

#### *FemTech Overcomes Barriers to Access*

The entry of FemTech solutions signals a market response to multiple studies which show that women face unique logistical and financial barriers to health care access. Women contend with scheduling challenges and balancing work and family responsibilities, barriers related to insurance and cost and dismissive or negative in-person encounters. Study participants frequently pointed to lack of resources for care postpartum while clinician interviewees noted lack of knowledge of disease burden, overmedicalization of women's care, deficits in care during postpartum and trends around changes in primary care.

Among the findings of a KFF Women's Health Survey (WHS) on women's health status, use of health care services and costs, responses showed that while the majority of women ages 18-64 report being in excellent, very good, or good health (82%), nearly one in five (18%) women describe their health as fair or poor. Half of women (49%) report having an ongoing health condition that requires regular monitoring, medical care, or medication and 18% report having a disability or chronic disease that keeps them from participating fully in work, school, housework, or other activities, with higher rates among older women. Ten percent of women with a disability or ongoing health condition do not have a regular doctor or health care provider.

#### *Here's Why Self-insured Companies and Employees Value FemTech*

- Flexibility of scheduling: FemTech solutions improve

the overall delivery of care, offering options for virtual clinic appointments, direct-to-consumer prescription delivery services and innovative physical clinics that provide greater convenience and consumer-friendly opportunities for easier access to care.

- Boosts recruitment and retention of key employees: Companies that integrate FemTech solutions report that these benefits are highly sought-after by female executives and staff. Offering these options positions employers to attract and retain the talent of many women who may not have these opportunities in another employment setting.
- Advances self-care: FemTech programs often include wearable devices, healthcare trackers and at-home diagnostics that support women in taking better charge of their own health and managing health-related data and information.
- Shines a light on stigmatized issues: FemTech companies are taking the lead in addressing topics that were once considered taboo or off limits, such as sexual health, menopause and menstrual health.
- Promotes health equity -- inclusive and culturally sensitive: Look to FemTech companies for products and services that serve previously marginalized groups, including Black women, under-resourced populations worldwide and LGBTQ populations.
- Tuned-in to the needs of women: Built by women, for women, FemTech startups are much likelier to be established and led by female entrepreneurs, positioning their organizations to better understand women's needs and problems. In fact, one analysis found that more than 70% of FemTech companies had at least one female founder, while non-FemTech companies hovered around 20%.
- Taps into valuable female technicians and scientists: Advancing gender equality in the tech sector, FemTech companies are overcoming gender stereotyping. These companies recognize the talent and capabilities of women who pursue a career in technology but may have been largely overlooked.

Erin Weenum reports that over the last several years, her organization has seen a dramatic shift in parents leaving the workforce due to childcare shortages and burnout.

"This has been especially true in healthcare and education sectors," she observes. "Employers need attractive benefits to recruit newly licensed professionals and to retain talent. Infertility coverage has been a consistent demand and differentiator in hard to recruit industries. Postpartum support for working parents, including paid leave, is no longer an optional benefit for most employers looking to recruit skilled workers."

Kimlinger reinforces that benefits are incredibly important for employer retention and recruiting, emphasizing, "I am a believer that the benefits package says a lot of about the culture and how an organization thinks about employee well-being -- we need to continue to see employees as whole people."

She says the workplace can serve as a significant safety net for employees and the concept of "checking work at the door when we start the workday" is antiquated.

"Work/life is integrated," says Kimlinger. "If a woman is coming back to work after having a baby and doesn't have access to support around mental health and her new life structure, it will not only impact the person but also their team and workplace."

When building a benefits structure, it's important to consider the lowest earning employees: "If you have employees making nearly minimum wage and then have pricey payroll contributions for a high deductible health plan that makes access nearly impossible, insurance really isn't useful for proactive care," stresses Kimlinger.

"If a woman is going back to work with post-partum depression and cannot afford therapy because they are paying dollar-for-dollar up to their deductible or she doesn't have the time to drive to a session, then this woman is at a significant disadvantage."

Dr. Barreto echoes this perspective, adding, "In a post-pandemic world, many employees are seeking employers that allow them to show up at work fully and authentically. They are seeking employers who support their full lived experience-- not just the person who shows up between the hours of 9 to 5."

She says that what many people don't realize is that these FemTech supported solutions aren't just for women -- men are beneficiaries of these programs as the women in their lives (wives, daughters) are able to tap into the services as well.

"This allows the reach of these programs to go that much further," she continues. "These are also more than 'just in time benefits'. While some employers may lean towards offering a home office stipend or a professional development stipend to attract and retain talent, there is really no comparison to helping an employee expand their family and/or live their life in good health."

#### *FemTech Services Designed for Employers*

Readers may be surprised to learn about some of the unique services that are now tailored to the needs of self-insured employers. For example, Dr. Adamson points to ARC Fertility's range of programs and benefits designed to meet the diverse needs of individuals and couples on their family-forming journeys, including:

- Intrauterine Insemination (IUI)
- In vitro Fertilization (IVF)
- Preconception Genetic Testing and Preimplantation Genetic Testing (PGT)
- Male fertility treatments, including testicular sperm aspiration (TESA) and microsurgical epididymal sperm aspiration (MESA)
- Egg freezing and banking
- Sperm, egg, and embryo donation
- Surrogacy
- Adoption
- Family-forming financing
- Emotional support
- FertilityNow app which serves as a go-to source, providing easy-to-use, evidence-based information at one's fingertips.

"Key to this approach is the commitment to affordability, quality, outcomes, cost-effectiveness, scalability and flexibility," says Dr. Adamson.

According to the U.S. Bureau of Labor Statistics, the workforce participation rate for women in July 2023 was 57.4%, which is 10.6 percentage points lower than men. Dr. Adamson advises that given ongoing talent supply chain challenges—in which skills shortages could cost companies worldwide trillions in unrealized revenue in the future -- organizations simply can't afford to leave talent pools untapped: "By offering family-forming benefits, employers can better attract women who are interested in starting a family -- and find this support a lever for joining a specific company."

**Couples Face Infertility**

Infertility is usually defined as the inability of a couple to conceive even after one year of unprotected, frequent sexual intercourse. While men's perceived support did not seem to influence their partners' stress, according to one study, evidence shows that partner support is significant in alleviating the burden of infertility and can affect the way men deal with these challenges. Male partners, social and family support influence infertility treatment and should be involved throughout the whole treatment process.

Experts report that the male is solely responsible in about 20% of cases and is a contributing factor in another 30% to 40% of all infertility cases. Industry sources say as male and female causes often co-exist, it is important that both partners are investigated for infertility and managed together.

According to several authorities, infertility affects about 15% of all couples in the United States, with male infertility defined as the inability of a male to make a fertile female pregnant after one year of unprotected intercourse. They say the male is solely responsible about 20% of the time and is a contributing factor in another 30% to 40% of all infertility cases. As male and female causes often co-exist, it is important that both partners are investigated for infertility and managed together. Some male fertility problems can be directly treated medically or surgically and assisted reproductive technologies (ART) can help almost all men conceive a pregnancy.

From the opposite perspective, a recently reported clinical trial showed interesting and promising data on an 'IUD for Men.' Adam is a male birth control product in which a nonhormonal gel is reported to be capable of blocking the flow of sperm to the vas deferens, with no serious adverse events having been reported. Stay tuned for updates and other products that are bound to follow.

**The Time is Now**

The FemTech market is set to grow over the next decade, in part because of the increased adoption of telemedicine, advances in technology, and the growing emphasis on sexual empowerment and reproductive health. Additionally, women are becoming more aware of the value of preventative care, the significance of timely detection and the importance of pro-actively managing conditions to potentially halt disease progression.

At the 2024 Nevada CES, one of the largest technology trade shows in the world where thousands of engineers,

entrepreneurs, dealmakers and tech companies shared their visions of what's next, several FemTech solutions were featured to help people with more personal health issues. Coverage of the event highlighted one start-up based in Ireland that plans to release a wearable sensor that tracks the frequency and severity of menopause symptoms, while another from South Korea claims to have developed a gadget targeting male fertility that will increase a wearer's sperm motility.

**Projected Growth of FemTech Market**


According to Precedence Research, the global FemTech market size accounted for USD 47.02 billion in 2022 and is expected to surpass around USD 108.78 billion by 2032, poised to grow at a compound annual growth rate (CAGR) of 8.8% during the forecast period 2023 to 2032.

Industry observers agree that FemTech solutions effectively address the historic lack of public discussion about women's health and reproductive issues. They can be credited for changing this landscape, as many startups have raised these issues and brought them into the mainstream. From January through August 2021, U.S. digital health startups catering to women raised \$1.3 billion -- almost twice the \$774 million raised throughout 2020, according to a report by Rock Health, a venture capital firm that supports digital health startups.

Some experts say the term FemTech is a misnomer as it implies that the women's healthcare market is a small, specialized market. Rather, many view this opportunity as a chance to offer healthcare advances for the billions of women in the workforce. According to the Bureau of Labor and Statistics (BLS), a review of the 2014-24 projected labor force data reveals that the share of women in the labor force is projected to increase from 46.8 percent in 2014 to 47.2 percent in 2024.

For those readers concerned about population growth and the value of FemTech, BLS states that in the long run, the fertility assumptions have the most impact on national population projections since fertility is often the largest component of population change. They report that it also has the greatest cumulative effect on population growth, because each extra birth adds not only to the next year's population, but also to the projected population for the person's entire lifespan.

Teri Weber advises that as with every strategic endeavor, "We encourage employers to first do a deep dive into its employee demographics and what is desired/expected from a benefits standpoint. Then, use those insights to find an intersection between what is valuable to employees



and what enables the organization to achieve more overarching objectives related to retention, productivity, DEI and the like."

workplace."

She says budget must also be a consideration, noting, "We do believe FemTech and, more broadly, a benefits program that supports comprehensive wellbeing as critical components to recruitment and retention. We also advise our employer clients not fall victim to point solution fatigue, and that everything implemented can be properly measured, monitored and promoted within the

Bottom-line: self-insured employers want to be ahead of the curve when it comes to supporting women's health. They are keenly interested in innovation, exemplified by FemTech solutions, as an opportunity to not only proactively address healthcare costs, but also create a workplace environment that places high value on women employees by delivering holistic benefits that are women-centered.



**Laura Carabello**

Chief Creative Officer, CPR Strategic Marketing and Communications

Laura Carabello, founder and principal owner of CPR Strategic Marketing and Communications, has worked with over 1,000 companies, including public and private organizations, as a strategic consultant. She has been instrumental in the growth and development of multiple organizations both domestic and worldwide. She currently serves on the International Committee of the Self Insurance Institute of America and serves as special advisor to the American Macular Degeneration Foundation. Recognized for innovation, Laura was on the founding team of Teladoc, the world's leading telemedicine company. She has been invited by the US Federal Trade Commission to testify on healthcare advertising and marketing ethics and was recently tapped to develop special projects for Forbes magazine. She is the publisher and managing editor of Medical Travel and Digital Health News, the authoritative, online business-to business international newsletter of the medical tourism industry covering US domestic and international medical travel.



# Conference Alert

## CONFERENCE ALERT

### North America

#### American Association of Neurological Surgeons Annual Meeting

May 3-6, 2024 | Chicago, Illinois

Website: <https://annualmeeting.aans.org/>

The AANS Annual Scientific Meeting is the premier event of the AANS, attended annually by more than 3,300 neurosurgeons and medical professionals. Attend to get insight into cutting-edge research and clinical discussion through workshops, seminars and hands-on sessions for practitioners at all levels.

#### CPHI North America

May 7-9, 2024 | Pennsylvania Convention Center, Philadelphia

Website: <https://www.cphi.com/northamerica/en/home.html>

CPHI has been uniting pharma professionals for over three decades. Through multi-channel events and digital platforms, CPHI engages and creates opportunities for the global supply chain. After establishment at 1990, CPHI has grown to become a community of over 280,000 professionals operating across the global supply chain.

#### BIO International Convention

June 3-6, 2024 | San Diego Convention Center, California

Website: <https://convention.bio.org/>

The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe. Whether you work at a public pharmaceutical company, biotech startup, academia, non-profits, and government or are a researcher, business development professional or investor, BIO is where you'll make valuable connections and build relationships. Our proprietary BIO One-on-One Partnering™ match-making platform—included in the Premier Access registration package—allows you to find potential partners, schedule and accept meetings.

#### Society of Robotic Surgery Annual Meeting

June 20-23 | Orlando, Florida

Website: <https://srobotics.org/>

This society is founded on the fundamental principles of education and collaboration as a means to tackle the complex issues of robotic surgery. This type of society gives us enormous possibilities in terms of multi-centric studies, database collection, fellowship training and funding support. We are an organization that will seek participation from residents and fellows and young faculty in the hope that we can assist them as they embrace robotics.

#### American Diabetes Association's 84th Scientific Sessions

June 21-24 | 2024, Orlando, Florida

Website: <https://professional.diabetes.org/scientific-sessions>

The ADA's Scientific Sessions, host to thousands of annual attendees, is the premier diabetes conference providing a platform to delve into the latest advancements in diabetes research, prevention, and care. Highlighting cutting-edge research and innovative treatment and care practices—the groundbreaking educational content is beneficial for both seasoned and early career professionals.

### Europe

#### London Biotechnology Show

May 8-9, 2024 | Olympia West, London, UK

Website: <https://londonbiotechshow.com/>

The London Biotechnology Show aims to be a premier biotechnology event in the UK and the broader European region to expedite the progress of biotechnology for revolutionizing medical & healthcare sectors globally. The event hosts a world-class exhibition and a comprehensive conference that will bring together leading policymakers, thought leaders, investors, industry experts, startups and other key stakeholders to network at the highest level, showcase innovative solutions, and identify new business opportunities in the field of Medicine & Healthcare sectors.

#### The MedTech Forum 2024

May 22-24, 2024 | Messe Wien, Vienna

Website: <https://www.medtecheurope.org/news-and-events/event/the-medtech-forum-2024/>

The MedTech Forum 2024 will take place in Vienna on 22-24 May. This year's edition promises to be an insightful and engaging experience, bringing together key players in the medical technology industry to explore the latest trends, innovations and opportunities. MTF 2024 is a place to meet industry experts dedicated to the advancement of healthcare, connect with like-minded people, forge new collaborations and contribute to the collective discussion shaping the future of our sector.

## CONFERENCE ALERT

### MedTech Summit

June 10-14, 2024 | DoubleTree by Hilton Brussels City, Brussels, Belgium

Website: <https://informaconnect.com/medtech-summit/>

As a hybrid event, MedTech Summit 2024 delegates will have the option to attend either in-person or digitally. All in-person presentations taking place in Brussels will be recorded and made available on-demand for 10 working days on our ConnectMe platform, and then for up to 12 months on our Streamly platform, for you to watch at a time that suits you.

## Asia

### CPHI Japan

April 17-19, 2024 | East Halls 4, 5 & 6, Tokyo Big Sight, Tokyo, Japan

Website: <https://www.cphi.com/japan/en/home.html>

CPHI has been uniting pharma professionals for over three decades. Through multi-channel events and digital platforms, CPHI engages and creates opportunities for the global supply chain. After establishment at 1990, CPHI has grown to become a community of over 280,000 professionals operating across the global supply chain.

### Bio Korea 2024 International Convention

May 8-10, 2024 | COEX, Seoul, Korea

Website: <https://www.biokorea.org/index.asp>


Since 2006, BIO KOREA has been holding the International Convention every year for invigorating and growing the global bio-health industry. This year also, we are pleased to announce the 19th BIO KOREA will be held on May 8-10, 2024 at COEX, Seoul. Through various programs of BIO KOREA 2024 including Business Partnering, Invest Fair, Exhibition, and Conference, exchange the newest bio-health trends and technology as well as get the global expansion business opportunity with various international academics, professionals, and CEOs of the global bio-health field.

### CPHI & PMEC China, Shanghai

June 19-21, 2024 | Shanghai New International Expo Center

Website: <https://beautyworld-japan.jp.messefrankfurt.com/tokyo/en.html>

CPHI has been uniting pharma professionals for over three decades. Through multi-channel events and digital platforms, CPHI engages and creates opportunities for the global supply chain. After establishment at 1990, CPHI has grown to become a community of over 280,000 professionals operating across the global supply chain.



# W MEDICAL STRATEGY GROUP

W Medical Strategy Group and its global network can lead your business to right solutions. Cruise on board with WMSG's in-depth expertise and accurate insights. We will navigate the world of health care industries to take you where you need to be.

Discover your destinations with us. Let the sailings begin.

[www.wmedical.org](http://www.wmedical.org)

**W**  
MEDICAL STRATEGY GROUP

**W Medical Strategy Group**

440 Sylvan Ave. Ste.290, Englewood Cliffs, NJ 07632

Tel. 201 408 5342

[www.wmedical.org](http://www.wmedical.org)

# Latest Healthcare Industry News

FEBRUARY 2024 - APRIL 2024



## 1. Celltrion Launches Zymfentra, a Subcutaneous Form of Infliximab

Celltrion USA introduces Zymfentra, the first subcutaneous infliximab formulation approved for moderate-to-severe active ulcerative colitis and Crohn's disease maintenance therapy. Priced at \$6,181.08 for two shots over four weeks, commercially insured patients receive copay assistance of \$5 per month. Uninsured or underinsured patients may qualify for free treatment. Unlike Inflectra, approved through the biosimilar process, Zymfentra underwent a stand-alone biologics license application. It boasts patent protection until 2037 for dosage form and 2040 for administration route. Supported by pivotal phase 3 data, Zymfentra showcases efficacy and safety comparable to placebo, with studies indicating low relapse risk post-switch from IV to subcutaneous administration. Presented at the European Crohn's and Colitis Organization, extended studies affirm its long-term benefits. As the pioneer of Remicade biosimilar, Celltrion extends its impact with Zymfentra's innovative delivery method, promising a new horizon in IBD treatment.

<https://www.managedhealthcareexecutive.com/view/zymfentra-the-first-subcutaneous-infliximab-is-approved-by-fda>

## 2. Johnson & Johnson boosts heart device business with \$12.5 billion Shockwave Medical deal

Johnson & Johnson (J&J) announces a \$12.5 billion acquisition of Shockwave Medical, expanding its cardiac health portfolio. The deal grants access to Shockwave's intravascular lithotripsy (IVL) device, which breaks down calcified plaque in heart vessels. J&J prioritizes cardiovascular products, evident in previous acquisitions like Abiomed and Laminar. With potential competition for Stelara, its flagship Crohn's disease drug, J&J seeks diversification. The acquisition, expected to close by mid-2024, values Shockwave at \$13.1 billion, reflecting its \$730.2 million product sales in 2023. Financed by cash and debt, the deal offers a 17% premium to Shockwave's stock price, signaling confidence in future growth.

<https://www.cnbc.com/2024/04/05/johnson-johnson-to-buy-shockwave-medical-for-12point5-billion.html>

## 3. FTC Issues Warning Letters to Pfizer, Thermo Fisher, and Others

The US Federal Trade Commission (FTC) issued "close-at-risk" letters to numerous companies, including Pfizer, Baxter International, and Thermo Fisher Scientific, warning of potential antitrust challenges post-deadline. Initiated between June 2021 and July 2022, these letters aim to regulate the surge in merger filings. Led by Chair Lina Khan, the FTC faced criticism from GOP commissioners and business groups for potentially hindering legitimate mergers. Despite issuing 204 warnings, the FTC hasn't dismantled any deals, with acquisitions like Pfizer's \$6.7 billion purchase of Arena Pharmaceuticals proceeding despite caution.

<https://www.pymnts.com/cpi-posts/ftc-issues-warning-letters-to-pfizer-thermo-fisher-and-others/>

## 4. Most Cancer Drugs Granted Accelerated FDA Approval May Not Work

A recent study scrutinizing the U.S. Food and Drug Administration's accelerated approval program for cancer drugs reveals that within five years, most of these medications fail to demonstrate improvements or extensions in patients' lives. Initiated in 1992 to expedite access to promising HIV drugs, today 85% of accelerated approvals target cancer treatments. However, despite early access, many drugs don't deliver anticipated benefits, with only 43% showing clinical advantages in follow-up trials. The study, discussed at the American Association for Cancer Research meeting, underscores the importance of transparent communication to patients regarding the uncertainty surrounding these accelerated approvals, especially considering their vital role in treating rare or advanced cancers.

<https://time.com/6964602/do-cancer-drugs-work/>

## 5. NASA, Health and Human Services Highlight Cancer Moonshot Progress

AstraZeneca and Daiichi Sankyo's Enhertu received accelerated approval from the FDA to treat advanced solid tumors in patients with HER2-positive (IHC 3+) expression who have undergone prior systemic treatment without satisfactory alternatives. HER2, a growth-promoting protein, is often associated with aggressive cancers. The FDA's decision was based on positive results from trials like DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02, showing significant objective response rates and duration of response. Dave Fredrickson of AZ highlighted Enhertu's role as the first ADC with a tumor-agnostic indication, emphasizing the importance of biomarker testing. Daiichi Sankyo's Ken Keller called it a milestone for eligible patients.

<https://www.nasa.gov/news-release/nasa-health-and-human-services-highlight-cancer-moonshot-progress/>

## 6. AstraZeneca, Daiichi Drug Gets Broad Tumor Approval in US

The White House is incorporating artificial intelligence (AI) into its Cancer Moonshot initiative, aiming to reduce the cancer death rate by half over 25 years and enhance the lives of patients and caregivers. Catherine Young, Assistant Director for Cancer Moonshot Engagement and Policy, emphasized the ambitious yet achievable goals and highlighted the role of AI in advancing the initiative. Key areas for AI implementation include aiding radiologists in faster cancer diagnosis, processing large data quantities, streamlining drug discovery and testing, and evaluating new drugs' effectiveness. Young stressed the need for proper controls to avoid exacerbating healthcare inequalities and biases in AI applications.

<https://www.bloomberg.com/news/articles/2024-04-08/astrazeneca-daiichi-drug-gets-broad-tumor-approval-in-us>

## LATEST HEALTHCARE INDUSTRY NEWS

### 7. FDA approves Merck's drug for rare, deadly lung condition

The FDA approved Merck's Winrevair for adults with pulmonary arterial hypertension (PAH), a rare and life-threatening lung condition. This marks a breakthrough as it targets the root cause, unlike existing drugs that manage symptoms. With a \$14,000 per vial price tag, Merck offers patient assistance programs. Winrevair enhances exercise capacity, mitigates PAH severity, and reduces disease progression risk. Projected as a \$5 billion annual sales by 2030, it's seen as a major revenue driver for Merck, especially as its key drug Keytruda nears market exclusivity. The drug, acquired through Acceleron Pharma, demonstrated significant efficacy in trials, offering hope to PAH patients.

<https://www.cnn.com/2024/03/26/fda-approves-merck-drug-sotatercept-for-rare-deadly-lung-condition.html>

### 8. BMS Sees Early ROI for \$14B Karuna Buy with Phase III Schizophrenia Win

Bristol Myers Squibb presented interim Phase III EMERGENT-4 study data at the SIRS 2024 Congress, revealing KarXT's promising results in treating schizophrenia. Over 75% of patients experienced at least a 30% improvement in symptoms at 52 weeks, with a notable drop in PANSS scores. KarXT, acquired from Karuna Therapeutics for \$14 billion, activates muscarinic receptors, differing from conventional treatments. Long-term safety data from EMERGENT-4 and EMERGENT-5 showed favorable tolerability and weight loss in patients. BMS plans to further discuss KarXT with the FDA, anticipating its PDUFA date in September 2024, aiming to offer a novel option for schizophrenia management.

<https://www.biospace.com/article/bms-sees-early-roi-for-14b-karuna-buy-with-phase-iii-schizophrenia-win/>

### 9. Novartis finally ready for Pluvicto filing in earlier prostate cancer as patient survival data clear up

Novartis is preparing to submit its radiotherapy Pluvicto for FDA approval in earlier-stage prostate cancer treatment, after favorable patient survival data from the PSMAfore trial. The trial showed Pluvicto's benefit against a comparator in metastatic castration-resistant prostate cancer. Novartis aims for a pre-chemo approval, crucial for its \$3 billion sales projection. Despite past delays due to immature data, Novartis plans to file in the second half of 2024. Concerns linger about the sustainability of survival trends. Novartis attributes past survival concerns to patient crossover. Similar issues occurred with Bristol Myers Squibb's Abecma, yet it gained FDA backing based on strong progression-free survival benefits.

<https://www.fiercepharma.com/pharma/novartis-finally-ready-pluvicto-filing-earlier-prostate-cancer-patient-survival-data-clear>

### 10. FDA Clears the First Digital Therapeutic for Depression, But Will Payers Cover It?

The FDA has cleared Rejoyn, a prescription digital therapeutic developed by Otsuka Pharmaceutical and Click Therapeutics, for treating major depressive disorder. Rejoyn delivers cognitive behavioral therapy lessons and exercises digitally, serving as an adjunct to antidepressant medication. Although the clinical trial showed a non-statistically significant difference compared to a sham app, Otsuka believes there is a trend favoring continued improvement. Rejoyn will be available for download this summer, with prescriptions sent electronically to pharmacies. Unlike previous digital therapeutics, Rejoyn benefits from Otsuka's support and existing market presence, potentially facilitating reimbursement. Pricing details are yet to be disclosed.

<https://medcitynews.com/2024/04/fda-clears-the-first-digital-therapeutic-for-depression-but-will-payers-cover-it/>



## Advancing Therapeutics, Improving Lives.

For more than 25 years, Gilead has worked to develop medicines that address areas of unmet medical need for people around the world.

Our portfolio of medicines and pipeline of investigational drugs include treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Every day we strive to transform and simplify care for people with life-threatening illnesses.



For more information, please visit [www.gilead.com](http://www.gilead.com).

We live in a time of uncertainties.  
Don't leave your healthcare to chance.  
Let Medical Korea be your guide to a new world of healing.

# MEDICAL KOREA

Where Your Health Begins Anew

